Clinical and radiological evidence of the recurrence of reversible pegvisomant-related lipohypertrophy at the new site of injection in two women with acromegaly: a case series
Abstract Introduction Pegvisomant-related lipohypertrophy may revert when changing the site of injection, but the lipohypertrophy may recur at the new site of injection.The strength of evidence, however, is weak and comes from information obtained from physical examination only.Case presentation We studied two Caucasian women with acromegaly, aged